MapLight shares sink on mixed ph. 2 schizophrenia readout
MapLight Therapeutics shares declined following the release of mixed Phase 2 trial results for its schizophrenia drug candidate.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
MapLight Therapeutics saw its stock price drop after reporting topline results from the ZEPHYR trial. The trial evaluated ML-007C-MA for the treatment of schizophrenia, with coverage describing the readout as mixed.
Reports from Fierce Biotech and BioPharma Dive highlight the decline in share price, though BioPharma Dive notes the stock sank despite some positive data. Finimize indicates that biotech and AI stocks were broadly impacted by the mixed news.
Meanwhile, TD Cowen has maintained a Buy rating for the company. Future focus remains on the detailed Phase 2 results for ML-007C-MA and the subsequent impact on MapLight's market valuation.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
What drug was tested in the trial?
The trial tested ML-007C-MA for the treatment of schizophrenia.
What was the name of the trial?
The trial was called the ZEPHYR trial.
How did analysts at TD Cowen respond to the data?
TD Cowen held a Buy rating for MapLight Therapeutics stock following the trial data.
Coverage (7)
- Maplight aims to differentiate muscarinic agonist from competitors BioWorld News · 9h ago
- MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose Yahoo Finance · 9h ago
- MapLight dives despite positive data for schizophrenia drug BioPharma Dive · 9h ago
- MapLight Therapeutics stock holds Buy rating at TD Cowen after trial data Investing.com · 9h ago
- Biotech And AI Stocks Got Hit On Mixed News Finimize · 9h ago
- Phase 2 Topline Results From ZEPHYR Trial: ML-007C-MA for the Treatment of Schizophrenia Psychiatric Times · 9h ago
- MapLight shares sink on mixed ph. 2 schizophrenia readout Fierce Biotech · 9h ago broke it first
People, places & organizations
Topics
Related trends
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plummeting after FDA staff disputed the company's claims of Phase 3 success for its DMD cell therapy.
Argenx to Buy Forte Biosciences for $2.2 Billion
Argenx is expanding its immunology pipeline through a $2.2 billion acquisition of autoimmune biotech company Forte Biosciences.
The 'Surprisingly Soft' Unit That Caused Danaher To Plummet
Danaher shares slide despite second-quarter earnings and revenue beats, driven by softness in its biotech unit.
Imaging study reveals widespread brain connection loss in schizophrenia
6 news sources are covering this Health story right now — Newsylist is tracking how fast it spreads.
Lilly Said to Near Deal for Psychedelic Drugmaker AtaiBeckley
Eli Lilly is reportedly nearing an acquisition of the psychedelic drugmaker AtaiBeckley, triggering significant movement in the company's share price.
Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits
8 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.